Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8794388 | Ophthalmology | 2017 | 11 Pages |
Abstract
Corneal collagen crosslinking for progressive keratoconus is cost effective at a willingness-to-pay threshold of 3 times the current gross domestic product (GDP) per capita. Moreover, a longer stabilizing effect of CXL increases cost effectiveness. If CXL had a stabilizing effect on keratoconus of 15 years or longer, then the ICER would be less than the 1Â Ã GDP per capita threshold and thus very cost effective.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Ophthalmology
Authors
Daniel A. MD, PhD, Marie-Josee J. PhD, Elsie MD, PhD, David P.S. MD, PhD, Saskia M. MD, PhD, G. Ardine PhD, Robert P.L. MD, PhD,